Business Context and Reporting Period
This Form 8-K was filed by Heatwurx, Inc. (not Processa Pharmaceuticals, Inc.) on May 30, 2014, reporting the completion of a private equity financing event. The company is incorporated in Delaware and headquartered in Gardena, CA.
Key Financial Metrics
- Transaction Type: Unregistered sale of Series D Units (Item 3.02).
- Units Sold: 171,987 Units (part of a total offering of 772,352 Units).
- Price per Unit: $3.00.
- Gross Proceeds: $515,962.
- Investors: 10 accredited investors.
- Securities Issued: 171,987 shares of Series D Preferred Stock and 85,992 warrants.
- Warrant Terms: Each whole warrant is exercisable at $3.00 per share.
- Conversion Terms: Series D Shares convert 1:1 into common stock at the holder's option, or at the company's option if the common stock trades at or above $4.50 for ten consecutive trading days.
Material Changes
The filing reports a discrete capital raise event rather than operational performance changes. The company successfully closed the second tranche of its Series D unit offering, raising approximately $516,000. No selling commissions or remuneration were paid in connection with this sale.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on operations, or specific risk factors beyond standard regulatory disclosures regarding the unregistered nature of the sale. The securities were sold under exemptions Section 4(a)(5), Section 4(a)(2), and Rule 506(b) of the Securities Act. Restrictive legends were imposed on the certificates.
Investor Verification Checklist
- Verify the registrant name is Heatwurx, Inc. and not Processa Pharmaceuticals, Inc.
- Confirm the total capital raised in the full Series D offering versus the partial close reported here ($515,962).
- Review the conversion trigger price ($4.50) relative to the current trading price of the common stock.
- Check for any subsequent filings regarding the remaining 600,365 Units available in the offering.